Good morning and welcome to the UnitedHealth Group Fourth Quarter and Full Year 2019 Earnings Conference Call. A question-and-answer session will follow UnitedHealth Group’s prepared remarks. As a reminder, this call is being recorded. Here is some important introductory information. This call contains forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. A description of some of the risks and uncertainties can be found in the reports that we file with the Securities and Exchange Commission, including the cautionary statements included in our current and periodic filings. This call will also reference non-GAAP amounts. A reconciliation of the non-GAAP to GAAP amounts is available on the Financial Reports & SEC Filings section of the company’s Investors page at www.unitedhealthgroup.com. Information presented on this call is contained in the earnings release we issued this morning and in our Form 8-K dated January 15, 2020, which maybe accessed from the Investors page of the company’s website. I will now turn the conference over to the Chief Executive Officer of UnitedHealth Group, David Wichmann. Please go ahead.

Good morning and thank you for joining us. Six weeks ago, we had the privilege of spending the day with many of you at our annual investor conference providing an in-depth look at the accelerating opportunities we see to serve more people, more deeply and to grow strongly into 2020 and well beyond. As we conclude 2019 and step into the New Year, the performance of our business strengthens our confidence in the themes, opportunities and outlooks of that day, as evidenced by today’s results. We remain highly focused on driving affordability, innovating with consumer and customer responsive products and services, improving operating performance and advancing NPS. Full year 2019 adjusted earnings per share were stronger than our investor conference outlook growing 17% for the year to $15.11 per share. Full year revenues exceeded $242 billion growing $16 billion over 2018 with notable gains in our Medicare, care delivery and pharmacy care services businesses. Full year cash flows were $18.5 billion or 1.3x net income. We finished the year encouraged by continued performance improvement in Medicaid. Early market interest in our new innovative line of employer sponsored benefit offerings and 2020 individual Medicare Advantage annual enrollment results, which were our strongest ever. Within our Medicare Advantage offerings including dual eligible growth, we expect to serve nearly 700,000 more people in 2020, the upper end of the range of performance offered at our investor conference. Our fourth quarter medical and operating cost positions continued to improve meaningfully enterprise-wide with ample opportunity for further progress on both of these fronts and our NPS improved nicely in 2019 across our businesses, particularly within network care providers, enrollees in Medicare Advantage and dual special needs plans as well as patients served by our OptumCare and pharmacy care services businesses. Improved costs and higher satisfaction…

Thank you, Dave. At Optum, we are encouraged and humbled by the expanding opportunities to grow and serve more people more deeply. There is a distinct energy and eagerness across our businesses as we enter 2020. In 2019, Optum revenues reached $113 billion growing 12% year-over-year. Total operating earnings grew 14% to $9.4 billion. OptumHealth revenues reached $30.3 billion in 2019, up 26% led by OptumCare, our care delivery business. We are steadily expanding into new geographies and expanding the depth and breadth of services in existing regions to further provide patients with the highest quality, convenient and affordable health services. One measure that helps illustrate how we are serving people more comprehensively is revenue per consumer served, which grew 26% in the quarter. This measure will continue strongly advancing as we further build out our integrated care delivery network. Turning to OptumRx, revenues of $74.3 billion grew 7% even with the previously discussed impact of the single large customer transition. The 2020 selling season for core pharmacy benefit services has now mostly concluded and it was our strongest ever. Through our other pharmacy care and specialty drug businesses, given our current positions we see significant opportunity to more fully serve patients’ pharmacy needs in their communities and drive better adherence and clinical outcome. At OptumInsight, revenues of $10 billion grew 11% and the revenue backlog was up 14% to $19.3 billion. OptumInsight perhaps more than any of our other businesses has a dual role; it has both unmatched capability to help distinguish our other businesses and serves as a profitable, growing externally facing business on its own. I would like to spend a few extra minutes this morning on how we view OptumInsight and why we are encouraged by its potential. I will start with the foundations. First, deep…

Thank you, Andrew. UnitedHealthcare is deeply embedded in every aspect of the health system from how to finance and pay for healthcare to engaging people and aligning incentives to promote healthier behaviors and better medicine to improve overall health at lower cost. UnitedHealthcare revenues grew by more than $10 billion to $194 billion in 2019. Operating earnings increased by 13% or $1.2 billion to $10.3 billion led by the strength in our Medicare and dual special needs businesses. As Dave noted, we are off to a strong start in Medicare Advantage this year. I would like to quickly share how we are helping to build the better health system: first, improving affordability; second, engaging and serving people; third, advancing product innovation; and fourth, serving through hands-on data-driven clinical care. Let’s start with affordability because that is the gating factor for greater access to care and improving the consumer experience. One of our goals is to engage more deeply with the highest performing physicians and other clinicians to advance both quality and affordability. We know these high-performing providers achieve considerably better health outcomes, while lowering the total cost of care. Our medical cost trend over the last 5 years has strongly outperformed financial average. We are committed to driving significantly lower rates in healthcare spending growth than the industry. We see billions of additional dollars in potential savings for consumers and customers from areas such as out site of service initiatives and more deeply embedding digital tools to reduce the administrative burden for physicians. We are also using digital and physical strategies to engage consumers in new ways to simplify their experience, reduce their financial burden, and lower the total cost of care. For example, for the nearly 1.5 million people enrolled in our motion program, we offer incentives for increased…

Thank you, Dirk. This morning, we reported full year revenues of $242 billion, up $15.9 billion or 7% year-over-year driven by double-digit revenue growth in Medicare and across Optum. Fourth quarter adjusted net earnings of $3.90 per share grew 19% and brought full year earnings to $15.11, growth of 17%. Cash flows from operations of $18.5 billion grew 18% over 2018 to 1.3x net income better than anticipated partly due to timing factors. Our balance sheet return metrics remained strong with return on equity of almost 26%. We ended the year with a debt to capital ratio of around 40%, even with over $10 billion of deployment for business combinations and CapEx, $5.5 billion in share repurchases and a 20% dividend increase. Medical reserves developed favorably in the fourth quarter by $270 million, including a $150 million from 2019. Overall, medical costs were well managed, resulting in an 82.5% medical care ratio for full year 2019. We continue to be highly attentive to operating costs as part of our overall affordability agenda. In 2019, our operating cost ratio of 14.5% improved 50 basis points, reflecting 60 basis points of operating cost productivity and the deferral of the health insurance tax partially offset by the effect of business mix changes and continued investments in innovation, service and growth. We enter 2020 with diversified growth momentum, balance sheet strength and financial flexibility. On earnings progression, we continue to expect 47% to 48% of full year earnings per share to be realized in the first half of the year, a point to keep in mind on that quarterly progression. 2019’s first quarter has one fewer work day than 2018’s resulting in a higher earnings level. This year, the first quarter had a more normal mix, but then adds an extra day due to leap year. Taken together, the day count shifting has a year-over-year impact on the medical care ratio of about 80 basis points. This will result in the first quarter 2020 MCR running higher than the second quarter and earnings per share progressing accordingly, with just under 55% of the first half earnings expected to be realized in the second quarter. These impacts of course were fully contemplated in that 2020 outlook we have provided at the beginning of December. For full year 2020, we continue to expect revenues to approach $262 billion and adjusted net earnings per share in a range of $16.25 to $16.55. Consistent with our prior practices, we will more formally address these and other expectations after the first quarter. With that, I will turn it back to Dave.

Thank you, John. As you can tell, we are confident in the outlook for our diversified and growing enterprise for 2020 and beyond. Our businesses remained strong and well-positioned for continued balanced growth by delivering even higher levels of suicidal value. We remain committed to our mission and an intense focus on serving one person at a time at increasing levels of value, more affordable, better outcomes and improved experiences while generating strong returns for you, our shareholders. Operator, let’s open it up for questions, one, per caller please.

[Operator Instructions] Thank you. We will take our first question from Justin Lake with Wolfe Research. Please go ahead.

Thanks. Good morning. Wanted to ask about the quarter in terms of medical cost, it looks like it came in better than you expected versus the update at the Investor Day. Any color there specifically if you can expand on how you are seeing kind of Medicaid progress from a cost and risk pool rate perspective as you kind of come into 2020 that will be really helpful as well? Thanks.

John Rex?

Hey, Justin. Good morning. Yes, I think I would point out a few things here. You are correct, it did come in just a little bit better than our guidance at the investor conference and a few things to note, first, I’d call it broadly across the businesses as we continue to see the impact of the affordability initiatives that we have been very focused having traction and having impacts. So broadly across that, I think it’s fair to say also that we certainly did see some continued improved in our Medicaid businesses, that’s a place that we have been focused on for a while here and that was also a contributor. But broadly, I would say, across our businesses as we saw those affordability initiatives having traction.

Thank you, Justin. Next question please.

Our next question is from A.J. Rice with Credit Suisse. Please go ahead.

Yes, just it sounds like on the call today you are reaffirming your expectations around Medicare Advantage enrollment, obviously CMS has come out with their January numbers. It looks like in terms of the percentage enrolled in January, you are a little bit lighter than you were a year ago, I don’t know if that’s a fair comparison, but I wondered is there anything in the data that I don’t know if you look at what they put out that is missing from your perspective? I know it shows you down in group MA and maybe you are going to pickup in group MA, but just you flush out a little further what group MA over the course of the year would anything to reassure us about your expectations around MA for this year?

Thanks, A.J. We are very pleased with our AEP results. And I would say that by far it’s our strongest year ever in individual Medicare. We did reaffirm the guidance, but nearer to the upper end of that guidance today, so we feel pretty strongly on with respect to our overall performance. Tim Noel, can you add some color on some of the other questions?

Yes, good morning A.J. Thanks for the question. And first off, some of that CMS partial AEP reporting can be a little bit misleading. And Dave said, first and foremost, we want to reiterate the confidence in our full year enrollment growth that we shared at investor conference for MA. And just to revisit that briefly, we said 500,000 to 550,000 Medicare Advantage growth in the M&R business, which includes both group and individual MA and we also said that would be up to 700,000 in MA growth, including duals lifting our community and state business. So when AEP completes, we will have grown by 370,000 in individual MA, including the duals that are in CNS and that’s up 140% over last year’s AEP and is our strongest performance ever in the annual enrollment period. We expect this to drive full year results about 700,000 member growth in individual MA and that’s split on January net growth versus the rest of the year is roughly 50-50 and that’s consistent with the historical pacing and also full year supported by the momentum that we have seen in AEP. With respect to group, you are right, group MA contracted modestly in the CMS reporting. When January all settles out, we expect that to be down about 65, but that will strengthen to flat to down 25 as the year closes out. And finally, all told, really great start to the year, strong signal of confidence for the full year and our growth guidance shared at investor conference.

Thank you, A.J. Next question please.

We will go next to Scott Fidel with Stephens. Please go ahead. Your line is open.

Thanks. I think just sticking on the membership updates for 2020 and obviously you just gave some good detail on Medicare. Just interested if there is anything to call out in terms of on either the commercial business or the Medicaid business in terms of expectations on membership relative to the ranges that you had provided at Investor Day? Then also just specifically within that, just interested in how you are sort of approaching the North Carolina Medicaid situation, just given the budget situation there in terms of what you are assuming for for timing implementation of that and how manly lives you have factored in around North Carolina? Thanks.

Good question, Scott. Thank you. Dirk McMahon will start and then Heather Cianfrocco can discuss Medicaid.

Yes, thanks. Thanks for the question, Scott. So, we will be down a little bit in enrollment for 01/01/20 in both the fully insured and ASO areas. But as throughout the course of the year, we expect to gain membership in both areas that we have previously guided in December. As we look at 2020 we are going to continue with the pricing discipline that I have previously talked about as we balance enrollment growth with our margin expectations. We remain focused on delivering a unique value proposition for our customers and the consumer. Just to tell you, we are optimistic for next year, I mean in fully insured, expect strength in individual products in their middle-market, as I look at your ASO block, I look at our All Savers and I look at our middle-market as well. And with that, turn over to Heather on Medicaid.

Thanks. Yes, so good question with respect to – I will start with membership and I will talk a little bit about North Carolina. So membership for this year we do expect growth in Medicaid this year and that’s coming from a couple of places, North Carolina is in our 2020 guidance right now. We have got some other things in there. We have got some increases from some markets like our Washington win last year, Texas win, recent Texas wins. We are going to see some Nebraska expansion and then we see another strong year [indiscernible] as Tim just talked about for 2020 we think we are really well positioned there with new county expansion, service area expansion and our AEP is off to a really, really strong start. We are really excited about that. Pressure is obviously North Carolina. So, it’s in our 2020 membership outlook and our revenue outlook and we assume it right now to come in about midyear. We are really honored we were selected. We are ready for implementation and we are eager to start serving North Carolinians. Despite the situation there, there is strong support for the program and for managed care there. So we are continuing to monitor the implementation date. We will keep you posted on that and you will watch that as well. In the meantime, we have got – we are excited about the opportunity, it’s in our outlook and we look forward to hopefully getting that on track here close to midyear as possible.

And just to add on to that a little bit, Scott, we won also in Kentucky, we are pleased to win obviously, that’s being re-bid now, but we will hopefully prevail in the end there as well and it’s a strong RFP season for Medicaid broadly. And I see the business having come around to being positioned with its turnaround just in time to compete ferociously for that business. So we are pretty bullish about the opportunity that exists in Medicaid and I think we are well positioned to grow. Thanks for the question, Scott. Next question please.

And we will go next to Peter Costa with Wells Fargo Securities. Please go ahead.

Good morning, everyone. Nice quarter. I’d like to take it up a little bit in terms of looking at some of the longer term picture for Medicare, just couple of changes in the Medicare program and I am curious what you think of as being the biggest risks to you in terms of your business and those are paying for social determinants of health, which is something new for this year allowing ESRD patients to join next year and Medicare fee-for-service direct contracting by providers is starting. Can you talk about those three items and if they are risks to you?

Sure. I would be happy to discuss all three of those. Tim?

Yes. Yes, thanks Peter. So I think I will take ESRD first, but also I want to caution the long-term outlook especially with respect to 2021 and really any year, it’s a little bit premature to get into some of the nuts and bolts of how we see the landscape shaping out. But on ESRD, we are very supportive of the change that goes into a fact that on 2021 and encouraged by the opportunity to serve more people. We are not concerned with some of the unknown elements around the reimbursement and payment idles. We will learn those details very soon. We remain confident and expecting that those models will be fair, adequate. And importantly, we believe that these people will be better served in Medicare Advantage. And also important to keep in mind, we served 40,000 Medicare Advantage enrollees with ESRD today that developed a disease post enrollment. And our focus of these members is both on prevention and also on treatment. So we are pleased to have the opportunity to expand our reach and impact with patients that have the disease at the time of enrollment. With respect to social determinants, we continue to have that be a key focus of our business consistently referring folks into insider programs where appropriate and some of the additional flexibility our apply social determinants and plan design are elements that we are leveraging in some of our demonstration projects in 2020. We are excited to learn a little bit more about this as the year progresses and look for more opportunities to do things in this area in 2021.

The last one was physician direct contracting fee-for-service Medicare.

Right. Hey, Peter. Brian Thompson here. We are very encouraged by that as well. I think similar to what we have done with the bundled payment program it’s a good opportunity to work on advancing traditional Medicare and we are encouraged by that thinking and creativity and look forward to participating.

And I might add overall, Peter, that we are bullish obviously overall on the outlook for both Medicare Advantage, but also the dual special needs marketplace as well. They are both very larger today and growing in markets. MA is clearly outperforming fee-for-service in terms of overall benefit coverages and the quality of outcomes and the returns that people are getting in terms of their overall satisfaction. And so no surprise that it is performing as well and seems to be gaining some momentum. So we look forward to continuing to compete hopefully growing at these levels, if not higher going forward. Next question please.

And we will take our next question from Josh Raskin with Nephron Research. Please go ahead.

Thanks. Good morning. Question around the sort of broad space that’s growing around physician enablement and I am curious it seems like there has been a lot of interest, a lot of new competitors that are kind of focused on that. I know Optum has been very early. Do you think of Optum as sort of the market leader and is this broad movement of physicians taking more risk, is this positive for UnitedHealth Group?

Josh thanks so much for the question. It’s Andrew. Yes, we absolutely see physicians very much as a central element of improving care delivery quality and cost. It was really driving OptumCare which is clearly the central part of OptumHealth. As we see physicians move toward taking more risk, we see improvements across the board in terms of resource allocation, prevention, focus, ensuring clinical outcome is maximized. We are very encouraged by that trend. This year alone we would expect about 150,000 more patients to go into our physician risk managed programs across OptumCare. We continue to see that trend accelerate. It’s very much something that we then anchored the build out of the rest of our OptumHealth portfolio around. So in a sense, is that thoughtfulness around how can we then create services inside data analytics which held the position, made the best possible judgment to manage the overall risk profile of the patient. You see that then reflected in the relentless growth of the revenue per patient served across OptumHealth. That’s really being driven by this shift. And so you are absolutely right, very important element for us and it essentially becomes the core around which we then envision and build our support services, our interventions and our analytics to empower the physicians to make the best possible decision on behalf of the patients. Thank you.

I might just add to that just slightly, Josh, that UnitedHealthcare is working on physician enablement as well. This is what the core of Dirk’s commentary this morning was around Point of Care Assist. This is why we built and deployed the IHR and this is why we focus essentially in our investor conference around the way in which we engage both the digital and physical realms to AI enabled people to be able to operate much more effectively and serve their patients. So thanks for the question.

We will go next to Kevin Fischbeck with Bank of America. Please go ahead.

Thanks. Just want to go back to Medicaid for a minute. Can you talk a little bit about, I think you mentioned that in Q4, maybe you saw some improvement on Medicaid, but can you talk about the expectation for the year, I guess in particular, I guess two things, one is the implication of redeterminations and the rate updates will get relative to that, how are the rate updates going and do you – are you modeling additional rate determinations as the year goes on? And then second just quickly going back to the North Carolina, if North Carolina got delayed into 2021, would that impact your EPS guidance or is it more towards the revenue number at this point?

Heather, do you want to take that question?

Sure. So maybe I will start with that Medicaid performance. So, yes, we are pleased with Q4 results and when I said that I really mean it’s marching along right within expectations with what we have really executed on our affordability agenda. We see strong partnership with our state to address what was for a period of time due to redeterminations or other under-funding issues, acquity-related under-funding. So as we look into 2020, I feel good about the progress made through all of ‘19 and particularly in the second half of ‘19 with respect to rates and with respect to affordability. And so as we come into 2020, we have got to view into our Q1 rate renewals. They are right in line with our expectations. They are up above what they were at the same time in ‘19. We have delivered on our clinical programs. We are seeing strong NPS, customer service scores and quality. So I feel good about that. As I say that, you still expect us to hit our target margin by the end of the year. So that just gives us renewed confidence in what was committed to you already, so expect our Medicaid business to continue to perform along that track and we will be hard at work on it. With respect to North Carolina, yes, I guess, I will just say, again we are monitoring it everyday right now, I am going to say that we are continuing to push and it is a big component of our opportunity in 2020 from revenue and a membership perspective. But that being said, there is a lot of other growth opportunities that we are measuring to. We didn’t have Kentucky in our guidance, but we also didn’t not got pushed, but we also didn’t have the Massachusetts care bid that we just won. So we are going to be monitoring all those things. And right now, we are going to kind of work for midyear or close thereto implementation and we will keep you posted.

Kevin, Dave again, if I can just add, so if North Carolina were to get pushed to 2021, it would not affect our expectations for the year, our guidance would stay the same. It is – as it comes out of the shoot it’s a relatively modest margin product, market as is often the case. So we wouldn’t expect any material impact on our expectations of the year. Thank you. Next question please.

And we will go next to Lance Wilkes with Bernstein. Please go ahead.

Yes. Could you talk a little bit about PBM margin for the quarter and interested in, I mean, the improvement there, how much of that is driven by just to make sure from the transition of the large clients and how much is other initiatives like cross sales or sourcing initiatives?

John Prince?

Lance thanks for the question. As you look at the fourth quarter, the margin was elevated as expected. So when we gave our guidance at Investor Day, we are expecting a operating earnings margin around 6.3%, 6.4%. So, it’s exactly what we expected. Why it was elevated is exactly what you mentioned was the loss of the large client, where we lost the revenue, but we didn’t really impact our operating earnings. The second driver was the supply chain strength in terms of our – continue to negotiate with pharma manufacturers as well as the supply chain to get value to pass on to our clients. And so that was the other key driver for us. As you look to 2020 guidance, you should expect our operating earnings margin to fallback to where we have guided at Investor Day with 5.1% to 5.2%, so that should be your expectation. It was more of an anomaly what happened in Q4 as expected.

Thank you, Lance. Next question please.

Yes. We will go next to Ricky Goldwasser with Morgan Stanley. Please go ahead.

Yes, hi, good morning. So, you reiterated guidance this morning for 2020, just want to clarify if the guidance already includes any impact from HIT repeal on midyear renewals and also the benefit from the Diplomat acquisition? And then another follow-up on the dual growth, I mean, obviously 15% to 20% is what is the implied growth which is strong and above market, but when we think about that, can you just kind of like help us think through the Part D dynamics and how that would slow through the P&L if it’s going to to have any impact on OptumRx throughout the year?

We will have John Rex started and then shift to Tim Wicks or John Prince.

Hey, Ricky. John Rex here. So in terms of those elements you mentioned, I’d say both immaterial in the scope of our company. You are correct, yes, when we guided to 2020 initially, the repeal of the HIT was the health insurance tax had not yet occurred, but I would call that immaterial to us, yes, there is some impact, but not material in terms of modest headwinds in the scheme of our company, not something that we would call out. Also in terms of the Diplomat, the pending Diplomat acquisition also, I would call that immaterial really no impact, really neutral in terms of our 2020 outlook.

And John Prince?

Thanks, Ricky. John Prince. In terms of the other pieces on Part D and other components, that’s as expected. So I think we are not changing our guidance for 2020. What we expected in terms of Part D and Diplomat was built into our guidance and so we are comfortable with our expectations.

Thank you, Ricky. Next question please.

We will go next to Stephen Tanal with Goldman Sachs. Please go ahead.

Good morning guys. Thanks for the question. I guess at this stage I was just wondering if you could give us a sense of the HIT repeal how we should be starting to thinking about modeling that in whether you commit to sort of at least the non-tax deductibility of it going away kind of falling to the bottom line or is it still too early? And then maybe just to your comment on OptumHealth just given the risk-taking nature of what you guys are doing, I thought it would be interesting to hear from you all how the flu impacted the economics of that business in Q4 thinking sort of revenue earnings margin? Thanks.

Great. I will touch on the HIT and then Wyatt Decker will comment on OptumHealth. So overall, the HIT, we are as I said in the prepared remarks, we are pleased that this would go away. Obviously, it’s great for seniors, families of small businesses and individual insurers as well on average for couple – senior couples $500 to $600 pretty much carries out the same for a family of four that’s sponsored by a small business. And so obviously, this has strong economic impact on these families and individuals. So it’s terrific to see it gets repealed. The other thing about it is it removes the excessive volatility. I am you are as fatigued with it as we are, it’s in, it’s out, and but more important in all of that is that, it affects the volatility of pricing in the marketplace as well. So hopefully we will see that stabilize as we get through 2020 and into 2021 as well. Just before I go to discuss 2021 and what our strategies maybe with respect to how we handle this, obviously, it’s important that the tax value gets back into the hands of people. That’s what it was intended to do and that’s what we intend to accomplish overall. And as John already indicated, while it has a drag on earnings for 2020 we are not changing our outlook as a result of that. That is small item in the broad scheme of things. And I think we are to discuss flu with OptumHealth.

Yes, Stephen, thank you for the question. At OptumHealth and OptumCare, we follow the usual flu modeling and we have not seen a material impact deviating from that in Q4 and we do not anticipate significant impact in Q1. As you may know, it’s been a reasonably robust flu season, but it’s mostly of the B strain which is not as severe. So we also have a fee-for-service MedExpress practice, which tends to offset any hit we might take on the risk side. Thank you.

Thank you, Wyatt. Just I want to clarify one thing that Ricky asked and I am not so sure we answered it correctly. It’s really about whether or not in Diplomat, the proposed transaction is in our numbers for 2021 and – or 2020 and the answer to that is no, it would not be in there. We don’t include transaction in our forecast until they closed. So that is not included in there. And as soon as it does close the quarter following we will update our forecast accordingly. This is one of the reasons why we talked about the impact of capital deployment on our growth rate and how it can advance during the year because of transactions. In this case, it will be very, very modest, but nonetheless, I just wanted to make sure we have that clarification. Thank you. Next question please.

We will go next to Steven Valiquette with Barclays. Please go ahead.

Thanks. Good morning, everybody. So actually not to beat the Diplomat Pharmacy acquisition topic at that, but I know it’s not a huge acquisition for you financially, but despite that, I do have to believe there would just almost immediately be a ton of operational synergies when folding that book of business into your existing PBM and specialty pharmacy operations, probably in reimbursement and also in pharmacy network contracts? So I guess I was hoping to hear more color around what you see is the biggest area of synergy at this stage? And then just conceptually, could this deal move the needle for UNH overall in 2021, obviously you are making it sound like probably in 2020 not much, but could it move the needle for the company overall in 2021? Thanks.

It will be nicely accretive to us. Unfortunately, it also comes with a great deal of integration costs, most of which will hit 2020 as well. And would you like to touch on that, John?

Steven it’s John Prince. Just maybe touch a bit more on why we are doing the deal, because I think that’s really at the core of it which was to better serve individuals that have complex diseases like oncology, immunology and specialized infusion therapy. When you look at the capabilities of Diplomat around specialty pharmacy and infusion, it fits well with the strategy of OptumRx focused on these unique populations that need better volume, helping improve their drug cost, improving their health outcomes and overall value of care and doing it in a compassionate way. So, we think it is a good fit of our two businesses that come together to better serve the key needs in the market. And so as we have talked about before strategically especially drug cost is a key focus for the future as well as polyclinics and I think that strategically fits very well. We are obviously still little ways away from closing the transaction. We are actively doing our planning for that. And we will be ready to start that as we conclude the transaction in the first quarter.

Okay, I appreciate the color. Thanks.

Yes, no problem. Next question please.

And we will go next to Michael Newshel with Evercore ISI. Please go ahead.

Thanks. Maybe just going back to the flu, I just wanted to confirm that those earlier comments also apply to the UnitedHealthcare side as well. You have seen high outpatient activity but severity in hospitalizations just don’t appear to be that high at least published yet?

Jeff Putnam?

Yes, thanks for the question. Yes, on the UnitedHealthcare side similar dynamics, the flu season as you see in the CDC data started early and we are having elevated incident levels on the outpatient side, but overall severity as was mentioned is lower there and in-patient admits have been close to normal, so very modest impact in the fourth quarter.

Thank you, Michael. Next question please.

We will go next to Ralph Giacobbe with Citi. Please go ahead.

Thanks. Good morning. You are rolling out certain initiatives and benefit design changes to your fully insured book around site of service initiatives and prior off along with preferred lab network, etcetera and it sounded like that actually benefited some – to some degree in the fourth quarter. Can you give us maybe a little bit of a sense of what proportion of the ASO book has adopted these initiatives maybe for 2020 and/or how we should think about sort of the uptake over time? Thanks.

I don’t think we will talk about adoption rates in the large national accounts business, but Dirk, do you want to talk a little bit about your overall efforts around containing medical costs?

Yes. As we think about medical costs, you mentioned very effectively site of service being rolled that out to a lot more codes in November, knees and procedures like that. We are also very focused on our network negotiations to try to drive unit costs lower in many areas. As we look at our trend, two-thirds of unit costs, the network is at the start of that. We are doing a lot of work in terms of increasing consumer engagement providing with them with effective decision tools to rally in our other apps portal to other digital properties to drive the right movements and also got to thank Optum, a lot of work with our clinical models driving savings as well as payment integrity as Andrew mentioned in his remarks. So, we really have a full forward press on affordability. We think that is a primary driver of our ability to price effectively in the market and actually provide access for consumers and employers and everyone, so a lot of work on the affordability front.

Dirk and team at UnitedHealthcare are doing a wonderful job on affordability broadly in medical cost. Obviously, they are interested in getting healthcare to be much more affordable and the collaboration between Optum UnitedHealthcare has never been stronger in that front. Optum has really stepped in as they do with all the third-party health plans as well. It’s really assist in driving this broad-based agenda across the company. We have time for two more questions. Next question please.

And we will go next to Gary Taylor with JPMorgan. Please go ahead.

Great. Does that mean I get to ask two questions? No.

Pardon me.

I was going to say, great, does that mean I get to ask two questions?

You can. We will answer the first one.

I will ask just my question. My one question is I do appreciate the earnings cadence commentary given the leap year, but thinking since reported MLR is such an outsized impact on the near-term stock volatility, wondering if you would be willing to give us first quarter MLR range, I mean there are a few other moving parts in the quarter besides leap year that was pretty high March seasonality with extra Monday, Tuesday and then obviously with the dilutive impact of the HIT reinstatement?

John Rex you, maybe just, I know that was pretty complex in terms of quarterly progression and we expected that. So John, you just want to make sure that everybody understands that well.

Sure, Gary. Good morning. Let me give you a little more color in terms of the impact that occurs as we go into that, but I described kind of some of the impacts with workdays content and how that flows. And just in terms of thinking about that, so when value different days with different medical costs, weekends versus weekdays even versus different days of the week. In terms of what I was describing there, it actually comes out to it, it’s a little – it’s not two days, it’s more than one day, it’s about 1.3 days of impact in terms of the workday content is where it fall then to when you flow into a leap year like that and that pattern, typically of course repeats. So that’s kind of the element that flows into that. Then if you consider the other elements we talked about at – when we talk to our full year MCR progression and year-over-year progression, we talked about the impact of the health insurance tax of 140 basis points and that impact and then we talked about mix impacts also that occur over the course of the year. So those are really kind of the cores that are as we consider, as we consider where we would expect the medical care ratio to be lining up here as we look at the first half of the year. I hope that gives you a little extra color.

So you don’t want to give us a 1Q range today?

Sorry, what’s that, Gary?

You don’t want to give us the first quarter MLR rate…

First quarter pick. I think I kind of just described it actually pretty, pretty hopefully fairly clearly there in terms of the roll forward and how you would approach that. So if you take the components of the math that I just gave you I think that should get you to a first quarter pick.

So there is no change to full year guidance. John tried to layout for you our first half last half would be and then within the first half what the proportions would be as well. So you should be able to get a pretty good sense of things from all of that recognizing oftentimes things don’t shoot quite that straight. So plus or minus would probably be a worthwhile range to put around whatever point estimate you come up with. Thank you very much Gary. Next question please.

And we will go next to Sarah James with Piper Sandler. Please go ahead.

Thanks for squeezing me in. Now that there is some bipartisan support for spread pricing though, can you talk about the exposure in ‘19 you said it was about 25% of the book so did that needle move for ‘20, what is the mix look like in your commercial book of spread versus pass through? And does this bill impact the value proposition that you see for OptumRx at all? Thanks.

John?

Sarah thanks for the question. As you know, we are committed to driving to a strategy around negotiating with the clients of a transparent model where more and more of our services are coming from administrative fees and value-based arrangements. Our clients decide how they want to pay for our services. So when we bid on a deal and for our client, we give them an opportunity either to pay through administrative fee or with spread or traditional. So it’s the client choice. So as you look at it, we don’t have a preference about where we want to go up in business model. We are in different on how a client wanted to choose it. In terms of the commercial market, the trend in the market hasn’t changed in the last several years. So actually the client is not going to move one way or the other in terms of spread versus administrative fee. As you look at the Medicaid market, there has been a trend over the last three years where more and more of the state organizations and have been moving to administrative fees. So if you looked at our client base 3 years ago, majority would have been spread. If you look at it today, less than a quarter is in spread and actually we expect that to almost disappear as you look out next year or 2 years. So from us when they actually impact our financials, I won’t speculate about what will happen in Washington, but we are well positioned from a business standpoint.

Great question, Sarah. Thank you so much. I will go ahead and close now. Thank you all for your questions. Sorry, we can’t get to everyone today. As you heard this morning, we remain confident in our outlook for 2020 and beyond. Our diversified and complementary businesses are strong and well-positioned for continued balanced growth by delivering even higher levels of societal value, while generating strong returns for you, our shareholders. Thank you and this concludes today’s call.

And this does indeed conclude today’s program. Thanks for your participation. You may now disconnect.